What is pathophysiology of Alzheimer?

['Déglul xët wii']

Lan mooy pathophysiologie bu alzheimer?

Jàngoroy Alzheimer (MA) dafay am ay doxalin yu jafe yuy tax ay proteen yuy dajaloo, ay metit, ak ay yëngu-yëngu yuy tax ay newron di yëngu.

Ñaari màndarga yu mag yu jàngoroy Alzheimer yi ñooy am amiloid-beta (Aβ) plaques ak neurofibrillary tangles (NFTs) ci biir bopp bi.

Amiloid-beta plaques yi dañuy juddoo ci ay ndamm ci proteine bu jiitu amiloid (APP) bu ñu ko jaxase ak ay enzymes ngir sàkk ay peptide Aβ.

Peptide yii dañuy daje di sos ay fibril yu dul jeex di dajaloo ci biti newron yi, di yàq jokkoo bi ci diggante newron yi, di indi deewu newron bi.

Dajale gii ay plaques Aβ la ñu jàpp ne mooy benn ci xew-xew yi njëkk a am ci juddug AD, te ñu jàpp ne moo tax ag wàll ci doxalin wuy wàññi yaram wi.

Ay jàmbur yuy tax ba ay neewrofibril di sosu bu proteen bu tau bi di am ay hyperphosphorylation di sos ay filaments yuy jafe-jafe ci biir ay neewron.

Yëngu-yëngu yooyu dañuy yàq liggéeyu microtubules yi, yu am solo ci jëme ay ndëgërlu ak yeneen yëngu-yëngu ci biir newron bi.

Xëpp yi mujj nañ indi dee ci neewon yi am jàngoro ji.

Yaram wi dafa am solo ci wàllu feebar bi.

Sistem imunite dafay tontu ci dajale plaque Aβ ak NFTs ci di génne ay cytokine yuy tax yaram tàmbalee tàng, loolu man na yokk musiba mi ci newron yi.

Te itam, am na ay firnde yuy wone ne, metitalu oxidatig, metitalu mitochondrial ak metitalu glucose bu yàqu dafay indi jàngoroy Alzheimer.

Lii lépp mën na indi ay feebar yuy yokk wàllu yaram, ba tax ñu dee.

Ci lu mujj, pathophysiologie bu jàngoroy Alzheimer dafay ànd ak ay sabab yu bari yuy tax ba xam-xam yi di wàññiku ak fàtte gi di wàññiku.

['Royuwaay:REF']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['Waxtaan: wér-gu-yaram']

['Web bii dañu koy defar ngir jàngal ak a xamle rekk te du ngir jox ay digal ci wàllu wér-gu-yaram walla ay liggéey yu ñu mën a def.']

['Xam-xam bi ñu leen di jox waruñu koo jëfandikoo ngir seet walla faj wér-gi-yaram walla jàngoro, te ñi bëgg a laaj ay leeral ci wàllu wér-gi-yaram war nañu seeti doktoor bu ñu nangu.']

['Seetal ne jàmbaar gii di sàkk tontu yi ci laaj yi, dafa ñàkk solo lool ci lu jëm ci limu limu nit ñi, niki limub ñi ñu jàngal ab jàngoro.']

['Danga war a wutal sa doktoor walla beneen fajkat bu am xam-xam ci lu jëm ci wér-gu-yaram. Bul sàggane walla nga gaaw a wutal sa doktoor ndax dara lu nga jàng ci dal bii. Soo xalaatee ne am nga lu la soxla ci wér-gu-yaram, wool 911 walla nga dem ci fajukaay bu la gën a jege ci saa si. Dal bii walla jëfandikoo ko taxul nga nekk ak ab doktoor walla ab jarag. BioMedLib walla ay liggéeykatam, walla kenn ci ñi koy jëfandikoo, duñu wax dara, muy lu leer mbaa lu leeradi, ci lu jëm ci xibaar yi ñu leen di jox fii walla ci ni ñu koy jëfandikoo.']

['Séddo: sañ-sañu jëfandikoo']

['Sàrtu sàmm-sañu-xët yi ñu bind ci Internet ci atum 1998 (Digital Millennium Copyright Act of 1998), 17 U.S.C. § 512 (ci angale mooy DMCA) dafay may boroom-sañu-xët yi ñu jàpp ne ay mbind yu feeñ ci Internet dañuy yàq seen sañ-sañ ci yoon wi ñu bind ci Amerig. ']

['Sudee gëm nga ci lu wér ne lenn ci li nekk ci sunu dal bi walla ci sunuy liggéey dafa moy say sañ-sañ, yaw (mbaa sa jawriñ) mën nga nu yónnee ab bataaxal di laaj ñu dindi li nekk ci dal bi walla ci liggéey bi, walla ñu téye sa jàll ci moom. ']

['Bind nañu ay yëgle ci mbind, ci ab bataaxal (Xoolal "Contact" ngir xam màkkaanu bataaxal bi).']

['DMCA dafa digle ne sa bataaxal bu jëm ci jàddug sañ-sañ bu ñu sos war na ëmb li ci topp: (1) xët wu jëm ci liggéey bi ñu sos ne jàdd nañ ko; (2) xët wu jëm ci li ñu sos ne jàdd nañ ko ak ay xibaar yu doy ngir may nu nu nu man a gis li mu ëmb; (3) ay xibaar yu jëm ci yaw, boole ci sa màkkaanu dal, sa limu telefóni ak sa màkkaanu imeel; (4) ab kàddu bu jóge ci yaw bu lay xamal ne am nga yaakaar bu wér ne li nga sos ci anam wi ñu la ko sosu, moom boroom sañ-sañ bi, walla ki ko dénk, walla benn yoon, nanguwu ko; ']

['(5) ab bataaxal bu ñu la jox, nga dëggal ci sa loxo ne li nga bind dëgg la te am nga sañ-sañu sàmm sañ-sañu jëfandikoo sañ-sañu bind bi ñu la sosal ne yàqu na;']

['ak (6) benn màndarga buy firndeel walla buy wone ay màndarga yuy wone ne moom la sañ-sañu jëfandikoo walla mu ngi koy jëfandikoo ci turu moom. ']

['Suñ la ci dugalul lépp lu ñu wax ci kaw, mën na tax ba say tawat di gaaw a jàppale.']

['Waxtaan']

['Yónneel nu ab imeel bu la laaj walla nga am ay xalaat.']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.